Cipla reports FY25 PAT higher 28.4% at Rs. 5,273 Cr
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
Glatiramer Acetate is the generic version of Copaxone 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
Raichur site is the group’s largest API facility and part of a wider network of seven sites
He has global experience in strategic and operational leadership levels with an extensive track record of leadership and success in building companies, businesses, teams, and brands for over 30 years
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
The approval marks Venus Remedies’ strategic entry into complex generics, expanding its injectable portfolio beyond traditional formulations
The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K.
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Subscribe To Our Newsletter & Stay Updated